Form 8-K - Current report:
SEC Accession No. 0001104659-22-129610
Filing Date
2022-12-22
Accepted
2022-12-22 17:27:49
Documents
16
Period of Report
2022-12-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2233327d1_8k.htm   iXBRL 8-K 37435
2 EXHIBIT 10.1 tm2233327d1_ex10-1.htm EX-10.1 130421
3 EXHIBIT 10.2 tm2233327d1_ex10-2.htm EX-10.2 65955
4 EXHIBIT 99.1 tm2233327d1_ex99-1.htm EX-99.1 16043
8 GRAPHIC tm2233327d1_ex99-1img001.jpg GRAPHIC 5060
  Complete submission text file 0001104659-22-129610.txt   496417

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA otlk-20221222.xsd EX-101.SCH 3322
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE otlk-20221222_lab.xml EX-101.LAB 34986
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE otlk-20221222_pre.xml EX-101.PRE 22617
10 EXTRACTED XBRL INSTANCE DOCUMENT tm2233327d1_8k_htm.xml XML 3695
Mailing Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830
Business Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 221482849
SIC: 2836 Biological Products, (No Diagnostic Substances)